Literatur
-
1
Hook E.
Ultrasound and fetal chromosome abnormalities.
Lancet.
1992;
349
1109
-
2
Kagan K O, Wright D, Baker A et al.
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Ultrasound Obstet Gynecol.
2008;
31
618-624
-
3
Nicolaides K H.
Screening for fetal aneuploidies at 11 to 13 weeks.
Prenatal Diagnosis.
2011;
31
7-15
-
4
Dagklis T et al.
Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Ultrasound Obstet Gynecol.
2008;
31
132-135
-
5
Merz E.
Ersttrimesterscreening – ein neuer Algorithmus der FMF-Deutschland zur Risikokalkulation von Chromosomenstörungen.
Ultraschall in Med.
2007;
28
270-272
-
6
Chaoui R, Thiel G, Heling K S.
Prevalence of an aberrant right subclavian artery (ARSA) in normal fetuses: a new soft marker for trisomy 21 risk assessment.
Ultrasound Obstet Gynecol.
2005;
26
256
-
7
Morris J K, Wald N J, Watt H C.
Fetal loss in Down syndrome pregnancies.
Prenatal Diagnosis.
1999;
19
142-145
-
8
Cash R, Manogaran M, Sroka H et al.
An assessment of women's knowledge of and views on the reporting of ultrasound soft markers during the routine anatomy ultrasound examination.
J Obstet Gynaecol Can.
2010;
32
120-125
-
9
Sonek J et al.
Frontomaxillary facial angle in fetuses with trisomy 21 at 11–13 weeks.
Am J Obstet Gynecol.
2007;
196
271.e1-271.e4
-
10
Borenstein M et al.
Frontomaxillary facial angle in chromosomally normal fetuses at 11 + 0 to 13 + 6 weeks.
Ultrasound Obstet Gynecol.
2007;
30
737-741
-
11
Borenstein M et al.
Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Ultrasound Obstet Gynecol.
2008;
32
5-11
-
12
Yang X et al.
Learning curve in measurement of fetal frontomaxillary facial angle at 11–13 weeks of gestation.
Ultrasound Obstet Gynecol.
2010;
35
530-534
-
13
Sonek J et al.
Frontomaxillary facial angles in screening for trisomy 21 at 14–23 weeks' gestation.
Am J Obstet Gynecol.
2007;
197
160.e1-160.e5
-
14
Lachmann R et al.
Frontomaxillary facial angle in fetuses with spina bifida at 11–13 weeks' gestation.
Ultrasound Obstet Gynecol.
2010;
36
268-271
-
15
Bottalico J N et al.
Second-trimester genetic sonogram for detection of fetal chromosomal abnormalities in a community-based antenatal testing unit.
Ultrasound Obstet Gynecol.
2009;
33
161-168
-
16
Slotnick R N, Abuhamad A Z.
Prognostic implications of fetal echogenic bowel.
Lancet.
1996;
347
85-87
-
17
Raniga S, Desari P, Parikh H.
Ultrasonographic soft markers of aneuploidy in second trimester: are we lost?.
MedGenMed.
2006;
8
9
-
18
Souka A P et al.
Increased nuchal translucency with normal karyotype.
Am J Obstet Gynecol.
2005;
192
1005-1021
-
19
Bilardo C M et al.
Increased nuchal translucency thickness and normal karyotype: time for parental reassurance.
Ultrasound Obstet Gynecol.
2007;
30
11-18
-
20
de Mooij Y M et al.
Aberrant lymphatic development in euploid fetuses with increased nuchal translucency including Noonan syndrome.
Prenat Diagn.
2011;
31
159-166
-
21
Evans M I, Van Decruyes H, Nicolaides K H.
Nuchal translucency measurements for first-trimester screening: the “Price” of Inaccuracy.
Fetal Diagn Ther.
2007;
22
401-404
-
22 Foundation F M. 11–13 week scan. Nuchaltranslucency. Protocol for measurement of nuchal translucency. http://http://www.fetalmedicine.com/fmf/training-certification/certificates-of-competence/11-13-week-scan/nuchal/ Accessed 15 May 2010
-
23
Abele H et al.
Intra- and interoperator reliability of manual and semi-automated measurement of fetal nuchal translucency by sonographers with different levels of experience.
Ultrasound Obstet Gynecol.
2010;
36
417-422
-
24
Nicolaides K H.
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Am J Obstet Gynecol.
2004;
191
45-67
-
25
Sonek J D et al.
Nasal bone assessment in prenatal screening for trisomy 21.
Am J Obstet Gynecol.
2006;
195
1219-1230
-
26
Murphy-Kaulbeck L, Dodds L, Joseph K S et al.
Single umbilical artery risk factors and pregnancy outcomes.
Obstet Gynecol.
2010;
116
843-850
-
27
Hua M, Odibo A O, Macones G A et al.
Single umbilical artery and its associated findings.
Obstet Gynecol.
2010;
115
930-934
-
28
Dagklis T et al.
Isolated single umbilical artery and fetal karyotype.
Ultrasound Obstet Gynecol.
2010;
36
291-295
-
29
Gornall A S, Kurinczuk J J, Konje J C.
Antenatal detection of a single umbilical artery: does it matter?.
Prenat Diagn.
2003;
23
117-123
-
30
Rembouskos G et al.
Single umbilical artery at 11–14 weeks' gestation: relation to chromosomal defects.
Ultrasound Obstet Gynecol.
2003;
22
567-570
-
31
Bethune M.
Literature review and suggested protocol for managing ultrasound soft markers for Down syndrome: Thickened nuchal fold, echogenic bowel, shortened femur, shortened humerus, pyelectasis and absent or hypoplastic nasal bone.
Australasian Radiol.
2007;
51
218-225
-
32
Papageorghiou A T et al.
Outcome of fetuses with antenatally diagnosed short femur.
Ultrasound Obstet Gynecol.
2008;
31
507-511
-
33
Bethune M.
Time to reconsider our approach to echogenic intracardiac focus and choroid plexus cysts.
Australian N Z J Obstet Gynaecol.
2008;
48
137-141
-
34
Lopez J A, Reich D.
Choroid plexus cysts.
J Am Board Family Med.
2006;
19
422-425
-
35
Bronsteen R et al.
Second-trimester sonography and trisomy 18: the significance of isolated choroid plexus cysts after an examination that includes the fetal hands.
J Ultrasound Med.
2004;
23
241-245
-
36
Gupta G, Aggarwal S, Phadke S R.
Intracardiac echogenic focus and fetal outcome.
J Clin Ultrasound.
2010;
38
466-469
-
37
Huang S-Y et al.
Intracardiac echogenic focus and trisomy 21 in a population previously evaluated by first-trimester combined screening.
Acta Obstetricia et Gynecologica Scandinavica.
2010;
89
1017-1023
-
38
Spencer K, Souter V, Tul N et al.
A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Ultrasound Obstet Gynecol.
1999;
13
231-237
-
39
Spencer K, Spencer C E, Power M et al.
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years prospective experience.
Brit J Obstet Gynaecol.
2003;
110
281-286
-
40
Avgidou K, Papageorghiou A, Bindra R et al.
Prospective first-trimester screening for trisomy 21 in 30 564 pregnancies.
Am J Obstet Gynecol.
2005;
192
1761-1767
-
41
Nicolaides K H, Spencer K, Avgidou K et al.
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Ultrasound Obstet Gynecol.
2005;
25
221-226
-
42
Spencer K, Souter V, Tul N et al.
Aneuploidy screening in the first trimester.
Am J Med Genet C Semin Med Genet.
2007;
145
18-32
-
43
Kagan K O, Wright D, Spencer K et al.
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Ultrasound Obstet Gynecol.
2008;
31
493-502
-
44
Wald N J, Rudnicka A R, Bestwick J P.
Sequential and contingent prenatal screening for Down syndrome.
Prenat Diagn.
2006;
26
769-777
-
45
Dugoff L et al.
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial).
Am J Obstet Gynecol.
2004;
191
1446-1451
-
46
Krantz D et al.
Association of extreme first-trimester free human chorionic gonadotropin-[beta], pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
Am J Obstet Gynecol.
2004;
191
1452-1458
-
47
Proctor L K et al.
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Ultrasound Obstet Gynecol.
2009;
34
274-282
-
48
Cuckle H S.
Screening for pre-eclampsia – lessons from aneuploidy screening.
Placenta.
2011;
32
S42-S48
-
49
Kirkegaard I, Uldbjerg N, Oxvig C.
Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
Acta Obstetricia et Gynecologica Scandinavica.
2010;
89
1118-1125
-
50
Akolekar R et al.
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks.
Prenat Diagn.
2011;
31
66-74
-
51
Nicolaides K H.
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Prenat Diagn.
2011;
31
3-6
-
52
Cole L.
Biological functions of hCG and hCG-related molecules.
Reprod Biol Endocrinol.
2010;
8
102
-
53
Lin T M, Galbert S P, Kiefer D et al.
Characterization of four human pregnancy-associated plasma proteins.
Am J Obstet Gynecol.
1974;
118
223-236
-
54
van Ravenswaaij R et al.
First-trimester serum PAPP-A and β-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome.
Prenat Diagn.
2011;
31
50-57
-
55
Torring N.
Performance of first-trimester screening between gestational weeks 7 and 13.
clinical chemistry.
2009;
55
1564-1567
-
56
Wright D et al.
First-trimester combined screening for trisomy 21 at 7–14 weeks' gestation.
Ultrasound Obstet Gynecol.
2010;
36
404-411
-
57
Kirkegaard I et al.
Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks.
Prenat Diagn.
2008;
28
839-844
F. Voigt
Frauenklinik des Universitätsklinikums Erlangen
Universitätsstraße 21–23
91054 Erlangen
eMail: franziska.voigt@uk-erlangen.de
